Speech difficulties and patient health communication mediating effects on worry and health‐related quality of life in children, adolescents, and young adults with Neurofibromatosis Type 1
Authors:
- 13 May 2019
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (8) , 1476-1482
Abstract
The objective was to investigate the serial mediating effects of speech difficulties, patient health communication, and disease‐specific worry in the relationship between neurofibromatosis (NF) symptoms (pain and skin symptoms) and total generic health‐related quality of life (HRQOL) in children, adolescents, and young adults with NF Type 1 (NF1) from the patient perspective. The Speech, Communication, Worry, Pain, Skin Itch Bother, and Skin Sensations Scales from the Pediatric Quality of Life Inventory (PedsQL) NF1 Module and the PedsQL 4.0 Generic Core Scales were completed in a multi‐site national study by 305 patients ages 5–25 years. A serial multiple mediator model analysis was conducted to test the hypothesized sequential mediating effects of speech difficulties, health communication, and worry as intervening variables in the association between NF1 symptoms and HRQOL. Symptoms predictive effects on total generic HRQOL were serially mediated by speech difficulties, patient health communication, and worry. In predictive analytics models utilizing hierarchical multiple regression analyses with age and gender demographic covariates, the pain, skin itch bother, and skin sensations multiple mediator models accounted for 61%, 59%, and 56% of the variance in generic HRQOL (p < .001), reflecting large effect sizes. Speech difficulties, patient health communication, and disease‐specific worry explain in part the mechanism of symptoms predictive effects on total generic HRQOL in pediatric patients with NF1. Identifying NF1‐specific predictors and serial mediators of total generic HRQOL in pediatric patients with NF1 from the patient perspective enables a patient‐centered comprehensive care approach for children, adolescents, and young adults with NF1.Keywords
Funding Information
- Neurofibromatosis Therapeutic Acceleration Program (2002129112)
This publication has 26 references indexed in Scilit:
- Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literatureJournal of Neuro-Oncology, 2015
- Neurofibromatosis type 1: a multidisciplinary approach to careThe Lancet Neurology, 2014
- Articulation in schoolchildren and adults with neurofibromatosis type 1Journal of Communication Disorders, 2012
- Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Frequency and Associated Clinical DeficitsThe Journal of Pediatrics, 2011
- Application of the International Classification of Functioning, Disability and Health in children with neurofibromatosis type 1: a reviewDevelopmental Medicine & Child Neurology, 2010
- Speech–language characteristics of children with neurofibromatosis type 1American Journal of Medical Genetics Part A, 2010
- Speech characteristics in neurofibromatosis type 1American Journal of Medical Genetics Part A, 2009
- The PedsQL™ 4.0 Generic Core Scales Young Adult VersionJournal of Health Psychology, 2009
- Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL™ 4.0 Generic Core ScalesHealth and Quality of Life Outcomes, 2007
- The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Journal of Personality and Social Psychology, 1986